NEW YORK, February 23, 2017 /PRNewswire/ --
This morning, Stock-Callers.com dedicates its attention to these Healthcare
Laval, Canada-based Valeant Pharmaceuticals International Inc.'s stock finished Wednesday's session 0.30% lower at $16.35 with a total trading volume of 9.69 million shares. The Company's shares have advanced 16.87% in the past month and 12.60% on an YTD basis. The stock is trading above its 50-day moving average by 10.63%. Furthermore, shares of Valeant Pharmaceuticals International, which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide, have a Relative Strength Index (RSI) of 63.76.
On February 14th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $29 a share to $22 a share.
On February 21st, 2017, Valeant Pharma and EyeGate Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. Your complete research report on VRX can be retrieved for free at:
Shares in Woonsocket, Rhode Island headquartered CVS Health Corp. ended at $80.16, up 0.50% from the last trading session. The stock recorded a trading volume of 4.97 million shares. The Company's shares have gained 8.92% in the previous three months and 2.20% since the start of this year. The stock is trading 0.98% above its 50-day moving average. Moreover, shares of CVS Health, which together with its subsidiaries, provides integrated pharmacy health care services, have an RSI of 57.96.
On February 06th, 2017, research firm Atlantic Equities downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On February 22nd, 2017, CVS Pharmacy reported that it is the first national retail pharmacy chain to announce the removal of partially hydrogenated oils, the primary source of artificial trans fats in processed foods, from all its exclusive store brands food products. The retailer now offers over 600 exclusive snack and grocery options which are free from artificial trans-fats. This comes a year and a half ahead of the Food and Drug Administration's deadline of June 2018 for processed foods to be reformulated without artificial trans-fats. A free report on CVS is just a click away at:
Saint Louis, Missouri headquartered Express Scripts Holding Co.'s stock ended yesterday's session 0.90% lower at $70.73 with a total trading volume of 2.61 million shares. The Company's shares have advanced 0.17% in the past month and 2.82% on an YTD basis. The stock is trading 1.13% above its 50-day moving average. Additionally, shares of Express Scripts Holding, which operates as a pharmacy benefit management (PBM) company in the US, Canada, and Europe, have an RSI of 58.59.
On February 16th, 2017, Express Scripts announced that it was recognized by Fortune Magazine as one of the World's Most Admired Companies within the Health Care: Pharmacy and Other Services category. Sign up for your complimentary research report on ESRX at:
At the close of trading on Wednesday, shares in Minnetonka, Minnesota-based UnitedHealth Group Inc. recorded a trading volume of 2.73 million shares. The stock finished flat at $160.57. The Company's shares have gained 0.94% in the last one month, 7.87% over the previous three months, and 0.33% on an YTD basis. The stock is trading above its 200-day moving average by 10.79%. Furthermore, shares of UnitedHealth Group, which operates as a diversified health and well-being company in the US, have an RSI of 47.88.
On February 21st, 2017, UnitedHealth Group commenced an exchange offer for all of the outstanding shares of Surgical Care Affiliates, Inc. (SCA) pursuant to the companies' previously announced merger agreement dated January 07th, 2017. Subject to terms and conditions of the Offer, which is being made through a wholly owned subsidiary of UnitedHealth Group, SCA's stockholders who validly tender their shares in the Offer will receive, for each share of SCA's common stock, cash and UnitedHealth Group common stock valued at $57.00. The Offer is scheduled to expire at 12:01 a.m., ET time on March 21st, 2017. Register for free on Stock-Callers.com and download the latest research report on UNH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All